Furthermore, the B3GALNT2 mRNA has been found overexpressed (by 2.56-fold) in breast cancer samples, especially from patients with TNBC [118], although B3GALNT2 was detectably downregulated in rhabdomyosarcoma [96] and kidney carcinoma (by ‒ 1.82-fold) [76] biopsy samples. This evidence concerns the gene B3GALNT2 and renal carcinoma.